<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132571</url>
  </required_header>
  <id_info>
    <org_study_id>1606017928</org_study_id>
    <nct_id>NCT03132571</nct_id>
  </id_info>
  <brief_title>Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia</brief_title>
  <acronym>NBC</acronym>
  <official_title>A Pilot Trial of Naltrexone-Bupropion Combination Versus Placebo Combined With Bupropion for Weight Loss in Comorbid Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of combining open-label extended
      release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus
      Bupropion and placebo along with a daily 500 calorie reduction diet recommendation for weight
      and health risk reduction in 40 overweight/obese individuals with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of naltrexone with noradrenaline/dopamine reuptake blocker bupropion has been
      developed and FDA-approved for the treatment of obesity in the general population. Naltrexone
      does not normally produce weight loss in humans and bupropion produces modest weight loss,
      however the combination produces clinically significant weight loss, which appears to be more
      than the sum of its components would otherwise produce separately. Of interest to us, the
      combination has been shown to be effective for clinically significant weight loss in obese
      subjects with type 2 diabetes as well. Registration studies by the manufacturer of the
      combination pill excluded antipsychotic medication users, thus we have no information on the
      potential effectiveness of the combination in this population. Both naltrexone and bupropion
      are commonly used in psychiatry, naltrexone for co-morbid alcohol addiction, and bupropion
      for co-morbid depression and/or cigarette addiction. This is a 16-week pilot trial of 37.5mg
      naltrexone/placebo added to extended release bupropion in flexible dosing (150mg to 450mg)
      and a daily 500 calorie reduction diet recommendation for subjects with schizophrenia and
      obesity. A dose of 37.5mg is similar to the FDA-approved combination dose for naltrexone.
      However, based on our experience with bupropion, we have chosen to use bupropion in an
      un-blinded manner and reach the target dose of 450mg based on tolerance of the individual
      subject over the initial 3-week period.

      Changes to the study since registration:

      The study was initially registered with 3 arms (Naltrexone vs Bupropion vs Placebo)- whereas
      the original intent was always supposed to be a 2 armed study (Naltrexone vs Placebo- each
      with Bupropion included)- this was corrected when the results of the terminated study were
      entered. In addition, there was an initial intent to include diabetics in the study, but this
      was later removed as well.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study discontinued due to funding.
  </why_stopped>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Naltrexone versus Placebo assignment will remain double-blinded for the duration of the study; Bupropion dosing will be open-label and not masked to either participant or investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>BMI will be calculated using weekly height and weight measurements (kg/m^2) at each assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>Weight in kilograms will be measured at each assessment and change will be determined at study endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Risk Markers</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Serum lipid profiles, fasting glucose, and glycosylated hemoglobin (hbA1c) will be measured at baseline and week 16 and change in these markers will be determined at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference (Inches)</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>Waist circumference will be measured in inches at each assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Naltrexone with Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Bupropion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>37.mg oral capsule taken once daily for over the course of the study (16 weeks)</description>
    <arm_group_label>Naltrexone with Bupropion</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
    <arm_group_label>Naltrexone with Bupropion</arm_group_label>
    <arm_group_label>Placebo with Bupropion</arm_group_label>
    <other_name>Wellbutrin</other_name>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo taken once daily for the course of the study (16 week)</description>
    <arm_group_label>Placebo with Bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age 18 to 75

          2. Meet DSM-IV criteria for schizophrenia or schizoaffective disorder based on SCID
             interview (If bipolar-schizoaffective: need to be adequately stabilized on a mood
             stabilizer and show no mania history for the past one year, as confirmed by study
             psychiatrist and patient's clinician)

          3. Body Mass Index (BMI) of 28 and over

          4. On a stable dose of antipsychotic medication; i.e. at least one month with no dose
             change, and three months from an antipsychotic switch

          5. Deemed to be symptomatically stable by the clinical staff in the last two months

          6. Over 7% total body weight increase on antipsychotics for subjects within first year of
             illness

        Exclusion Criteria

          1. Meet criteria for current opiate abuse or dependence (confirmed by positive urine drug
             screen for opiates or, if suspected by study doctor via patient history and or
             suspicion of occult opiate use.) Note: All subjects will be screened for drugs, not
             only those suspected of opiate use.

          2. A history of seizures in the past five years (confirmed through chart review and
             discussion with patient's clinician)

          3. Meet DSM criteria for Bipolar Disorder

          4. History of mania in the past one year (confirmed through chart review and discussion
             with patient's clinician)

          5. Uncontrolled hypertension

          6. Insulin dependent diabetes mellitus

          7. Current history of dementia, mental retardation

          8. Not capable of giving informed consent for participation in the study

          9. Women who are pregnant or breast-feeding

         10. Physical conditions affecting body weight (e.g. Cushing's disease, polycystic ovary
             syndrome)

         11. Severe liver dysfunction, (serum aminotransferases greater than three times normal),
             acute infectious hepatitis, liver failure.

         12. History of glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cenk Tek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <results_first_submitted>June 28, 2019</results_first_submitted>
  <results_first_submitted_qc>August 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2019</results_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All de-identified data resulting from this award involving human subjects will be submitted to the NIMH Data Archive (NDA) - National Database for Clinical Trials Related to Mental Illness (NDCT) The Principal Investigator will work with NDA support staff to plan an appropriate data submission schedule and provide information on the steps for submission and sharing of data. Communication of this data sharing plan to appropriate research staff to ensure the timely submission of data. All human subject data provided will include an NDA Global Unique Identifier (GUID) and will not include personally identifiable information (PII). Analyzed data will be submitted no later than the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset will be submitted when the first paper is published. All data made available for public use via NDA will be de-identified data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03132571/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>30 people were screened by telephone.
18/30 people screened were deemed ineligible. The reasons for ineligibility were: antidepressant medication use (11/18), a history of seizures (4/18) and already taking Naltrexone (3/18).
12/30 people were eligible, 6/12 were initially interested in the study and ultimately, only 5/6 were consented.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone With Bupropion</title>
          <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
Naltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
        </group>
        <group group_id="P2">
          <title>Placebo With Bupropion</title>
          <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Placebo: Oral placebo taken once daily for the course of the study (16 week)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone With Bupropion</title>
          <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
Naltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
        </group>
        <group group_id="B2">
          <title>Placebo With Bupropion</title>
          <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Placebo: Oral placebo taken once daily for the course of the study (16 week)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.33" spread="8.14"/>
                    <measurement group_id="B2" value="58.00" spread="1.41"/>
                    <measurement group_id="B3" value="51.00" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BMI</title>
        <description>BMI will be calculated using weekly height and weight measurements (kg/m^2) at each assessment.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone With Bupropion</title>
            <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
Naltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Bupropion</title>
            <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Placebo: Oral placebo taken once daily for the course of the study (16 week)</description>
          </group>
        </group_list>
        <measure>
          <title>BMI</title>
          <description>BMI will be calculated using weekly height and weight measurements (kg/m^2) at each assessment.</description>
          <population>Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.06" spread="6.03"/>
                    <measurement group_id="O2" value="29.55" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.33" spread="5.81"/>
                    <measurement group_id="O2" value="30.65" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight (kg)</title>
        <description>Weight in kilograms will be measured at each assessment and change will be determined at study endpoint.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone With Bupropion</title>
            <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
Naltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Bupropion</title>
            <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Placebo: Oral placebo taken once daily for the course of the study (16 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Weight (kg)</title>
          <description>Weight in kilograms will be measured at each assessment and change will be determined at study endpoint.</description>
          <population>Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.78" spread="11.17"/>
                    <measurement group_id="O2" value="87.25" spread="15.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.60" spread="11.24"/>
                    <measurement group_id="O2" value="91.25" spread="27.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Risk Markers</title>
        <description>Serum lipid profiles, fasting glucose, and glycosylated hemoglobin (hbA1c) will be measured at baseline and week 16 and change in these markers will be determined at endpoint</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>These labratory data were not collected and summarized due to the removal of diabetes from the study criteria and the early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone With Bupropion</title>
            <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
Naltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Bupropion</title>
            <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Placebo: Oral placebo taken once daily for the course of the study (16 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Health Risk Markers</title>
          <description>Serum lipid profiles, fasting glucose, and glycosylated hemoglobin (hbA1c) will be measured at baseline and week 16 and change in these markers will be determined at endpoint</description>
          <population>These labratory data were not collected and summarized due to the removal of diabetes from the study criteria and the early termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference (Inches)</title>
        <description>Waist circumference will be measured in inches at each assessment.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone With Bupropion</title>
            <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
Naltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Bupropion</title>
            <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Placebo: Oral placebo taken once daily for the course of the study (16 week)</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference (Inches)</title>
          <description>Waist circumference will be measured in inches at each assessment.</description>
          <population>Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.</population>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.08" spread="5.26"/>
                    <measurement group_id="O2" value="41.87" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.50" spread="5.76"/>
                    <measurement group_id="O2" value="43.37" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored in patients up to 16 weeks post randomization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone With Bupropion</title>
          <description>Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
Naltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.</description>
        </group>
        <group group_id="E2">
          <title>Placebo With Bupropion</title>
          <description>Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
Bupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Placebo: Oral placebo taken once daily for the course of the study (16 week)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cenk Tek</name_or_title>
      <organization>Yale School of Medicine, Department of Psychiatry</organization>
      <phone>(203) 974-7500</phone>
      <email>cenk.tek@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

